Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis

Core Insights - Kymera Therapeutics announced positive clinical results from the BroADen Phase 1b trial of KT-621, a first-in-class oral STAT6 degrader for atopic dermatitis (AD), demonstrating significant efficacy and safety [1][2][26] Study Results - KT-621 achieved median STAT6 degradation of 94% in skin and 98% in blood across both 100 mg and 200 mg dose groups, indicating strong translation from healthy volunteers to AD patients [1][7] - Significant reductions in Type 2 inflammatory biomarkers were observed, including a 74% median reduction in TARC for patients with baseline levels comparable to dupilumab studies [1][8] - Clinical endpoints showed robust activity, with a mean EASI reduction of 63% and a mean peak pruritus NRS reduction of 40% across all patients [1][15] Comorbid Conditions - In patients with comorbid asthma, KT-621 achieved a median FeNO reduction of 56%, indicating potential benefits for asthma control [1][21] - Patients with comorbid allergic rhinitis experienced significant improvements in symptom scores, demonstrating KT-621's broader applicability in Type 2 inflammatory diseases [1][22] Safety Profile - KT-621 was well-tolerated with no serious adverse events reported, consistent with findings from the Phase 1a study [4][23] Next Steps - The ongoing BROADEN2 Phase 2b trial in moderate to severe AD patients is expected to report data by mid-2027, while the BREADTH Phase 2b trial in asthma is set to start in Q1 2026 [4][24] Company Overview - Kymera Therapeutics is focused on developing oral small molecule degraders to address immunological diseases, with KT-621 being the first STAT6-directed drug in clinical evaluation [26][27]